P R Rutgeerts

Summary

Affiliation: Katholieke Universiteit Leuven
Country: Belgium

Publications

  1. pmc A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis
    Paul J Rutgeerts
    Department of Medicine, Division of Gastroenterology, University of Leuven, Herestraat 49, 3052 Leuven, Belgium
    Gut 62:1122-30. 2013
  2. doi request reprint How to guide therapeutic decisions in a patient-tailored approach to treatment of IBD?
    Paul Rutgeerts
    University of Leuven, Leuven, Belgium
    Dig Dis 30:396-9. 2012
  3. ncbi request reprint Anti-TNF strategies in Crohn's disease: mechanisms, clinical effects, indications
    F J Baert
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Int J Colorectal Dis 14:47-51. 1999
  4. ncbi request reprint Optimizing anti-TNF treatment in inflammatory bowel disease
    Paul Rutgeerts
    Department of Medicine, Division of Gastroenterology, University of Leuven, Belgium
    Gastroenterology 126:1593-610. 2004
  5. ncbi request reprint Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease
    Paul Rutgeerts
    Afdeling Gastroenterologie, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
    Gastroenterology 126:402-13. 2004
  6. ncbi request reprint Review article: treatment of perianal fistulizing Crohn's disease
    P Rutgeerts
    University of Leuven, Belgium
    Aliment Pharmacol Ther 20:106-10. 2004
  7. ncbi request reprint Review article: Infliximab therapy for inflammatory bowel disease--seven years on
    P Rutgeerts
    Department of Medicine, Division of Gastroenterology, University of Leuven, Leuven, Belgium
    Aliment Pharmacol Ther 23:451-63. 2006
  8. pmc Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?
    Paul Rutgeerts
    University Hospital Gasthuisberg, Department of Gastroenterology, Herestraat 49, Leuven 3052, Belgium
    Gut 56:453-5. 2007
  9. ncbi request reprint Onercept for moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial
    Paul Rutgeerts
    University Hospital Gasthuisberg, Leuven, Belgium
    Clin Gastroenterol Hepatol 4:888-93. 2006
  10. ncbi request reprint Review article: recurrence of Crohn's disease after surgery - the need for treatment of new lesions
    P Rutgeerts
    Division of Gastroenterology, University Hospital, Leuven, Belgium
    Aliment Pharmacol Ther 24:29-32. 2006

Detail Information

Publications100

  1. pmc A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis
    Paul J Rutgeerts
    Department of Medicine, Division of Gastroenterology, University of Leuven, Herestraat 49, 3052 Leuven, Belgium
    Gut 62:1122-30. 2013
    ..This randomised phase I study evaluated the safety and pharmacology of etrolizumab in patients with moderate to severe UC...
  2. doi request reprint How to guide therapeutic decisions in a patient-tailored approach to treatment of IBD?
    Paul Rutgeerts
    University of Leuven, Leuven, Belgium
    Dig Dis 30:396-9. 2012
    ..Treatments that do not heal (or at least improve) ulcers are not to be continued if they have been given a reasonable time to work. Biomarkers like C-reactive protein and calprotectin can be useful surrogates in this setting...
  3. ncbi request reprint Anti-TNF strategies in Crohn's disease: mechanisms, clinical effects, indications
    F J Baert
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Int J Colorectal Dis 14:47-51. 1999
    ..Careful monitoring of safety of repeated and long-term use of these agents, interfering with very basic physiological events, is mandatory...
  4. ncbi request reprint Optimizing anti-TNF treatment in inflammatory bowel disease
    Paul Rutgeerts
    Department of Medicine, Division of Gastroenterology, University of Leuven, Belgium
    Gastroenterology 126:1593-610. 2004
    ..Other adverse events associated with anti-TNF strategies are demyelinating disease and worsening of congestive heart failure. Malignancy rates in patients treated with anti-TNF strategies do not seem to be increased...
  5. ncbi request reprint Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease
    Paul Rutgeerts
    Afdeling Gastroenterologie, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
    Gastroenterology 126:402-13. 2004
    ..This analysis of Crohn's disease patients treated with infliximab in ACCENT I compared episodic and scheduled treatment strategies under conditions that simulate clinical practice...
  6. ncbi request reprint Review article: treatment of perianal fistulizing Crohn's disease
    P Rutgeerts
    University of Leuven, Belgium
    Aliment Pharmacol Ther 20:106-10. 2004
    ..A treatment algorithm for fistulizing Crohn's disease must therefore involve the early and optimal use of immunosuppression and of infliximab. Medical and surgical co-operation is also critical to achieve the best possible outcome...
  7. ncbi request reprint Review article: Infliximab therapy for inflammatory bowel disease--seven years on
    P Rutgeerts
    Department of Medicine, Division of Gastroenterology, University of Leuven, Leuven, Belgium
    Aliment Pharmacol Ther 23:451-63. 2006
    ..There is no evidence that malignancy rates in patients treated with antitumour necrosis factor strategies are increased...
  8. pmc Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?
    Paul Rutgeerts
    University Hospital Gasthuisberg, Department of Gastroenterology, Herestraat 49, Leuven 3052, Belgium
    Gut 56:453-5. 2007
    ..We propose that future studies should focus on healing and disease course as primary outcome measures...
  9. ncbi request reprint Onercept for moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial
    Paul Rutgeerts
    University Hospital Gasthuisberg, Leuven, Belgium
    Clin Gastroenterol Hepatol 4:888-93. 2006
    ..Onercept is a recombinant, soluble human p55 receptor to tumor necrosis factor-alpha...
  10. ncbi request reprint Review article: recurrence of Crohn's disease after surgery - the need for treatment of new lesions
    P Rutgeerts
    Division of Gastroenterology, University Hospital, Leuven, Belgium
    Aliment Pharmacol Ther 24:29-32. 2006
    ....
  11. pmc Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn's disease
    Paul Rutgeerts
    Division of Gastroenterology, University Hospital Leuven, Leuven, Belgium
    Int J Colorectal Dis 23:289-96. 2008
    ..In this paper, we report the effect of certolizumab pegol on health-related quality of life (HRQoL)...
  12. ncbi request reprint Infliximab for induction and maintenance therapy for ulcerative colitis
    Paul Rutgeerts
    University Hospital Gasthuisberg, Leuven, Belgium
    N Engl J Med 353:2462-76. 2005
    ..Infliximab, a chimeric monoclonal antibody directed against tumor necrosis factor alpha, is an established treatment for Crohn's disease but not ulcerative colitis...
  13. ncbi request reprint Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial
    Paul Rutgeerts
    Department of Gastroenterology, University Hospital Gasthuisberg, 3000 Leuven, Belgium
    Gastroenterology 128:856-61. 2005
    ..We investigated the efficacy and safety of ornidazole, a nitroimidazole antibiotic, for the prevention of clinical recurrence of Crohn's disease after curative ileocolonic resection in a placebo-controlled double-blind clinical trial...
  14. pmc Protagonist: Crohn's disease recurrence can be prevented after ileal resection
    P Rutgeerts
    Internal Medicine, Division of Gastroenterology, University Hospital, Gasthuisberg, Leuven, Belgium
    Gut 51:152-3. 2002
  15. doi request reprint Biological therapies for inflammatory bowel diseases
    Paul Rutgeerts
    Division of Gastroenterology, University of Leuven Hospitals, Leuven, Belgium
    Gastroenterology 136:1182-97. 2009
    ..The efficacy of each therapy must be shown in carefully designed clinical programs. Biological therapies carry a definite safety risk, so their place in treatment algorithms must be defined carefully...
  16. doi request reprint Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial
    Gert Van Assche
    Division of Gastroenterology, University of Leuven Hospitals, Leuven, Belgium
    Gastroenterology 134:1861-8. 2008
    ..We aimed to study the influence of immunosuppressives discontinuation in patients in remission with combination therapy in an open-label, randomized, controlled trial...
  17. pmc Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease
    Liesbet Henckaerts
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Gut 56:1536-42. 2007
    ..Materials and..
  18. pmc Treatment of severe steroid refractory ulcerative colitis
    Gert Van Assche
    Division of Gastroenterology, University of Leuven Hospitals, Herestraat 49, Leuven, Belgium
    World J Gastroenterol 14:5508-11. 2008
    ..Therefore, patients not responding to these agents within 5-7 d should be considered for colectomy and responders should be closely monitored for infections...
  19. ncbi request reprint Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease
    Paul Rutgeerts
    Afdeling Gastroenterologie, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
    Gastrointest Endosc 63:433-42; quiz 464. 2006
    ....
  20. ncbi request reprint NOD2/CARD15 does not influence response to infliximab in Crohn's disease
    Severine Vermeire
    Department of Gastroenterology, UZ Gasthuisberg, Leuven, Belgium
    Gastroenterology 123:106-11. 2002
    ..It is not clear which factors influence treatment outcome. We assessed whether variants in NOD2/CARD15 are predictive for differences in clinical response...
  21. doi request reprint Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease
    Filip Baert
    Department of Gastroenterology, H Hartziekenhuis Roeselare Menen vzw, Roeselare, Belgium
    Gastroenterology 138:463-8; quiz e10-1. 2010
    ..Few prospective data are available to support the clinical relevance of mucosal healing in patients with Crohn's disease. This study examined whether complete healing, determined by endoscopy, predicts a better outcome in Crohn's disease...
  22. ncbi request reprint Mucosal healing and anti TNFs in IBD
    Gert Van Assche
    Department of Gastroenterology, Leuven University Hospitals, 49 Herestraat, Leuven, Belgium
    Curr Drug Targets 11:227-33. 2010
    ..In clinical practice assessing mucosal healing should be considered in patients with persistent symptoms despite adequate therapy and when treatment discontinuation is being considered...
  23. doi request reprint Pouchitis, similar to active ulcerative colitis, is associated with impaired butyrate oxidation by intestinal mucosa
    Vicky De Preter
    Department of Gastrointestinal Research and Leuven Food Science and Nutrition Research Centre LFoRCe, University Hospital Leuven, KU Leuven, Leuven, Belgium
    Inflamm Bowel Dis 15:335-40. 2009
    ..The aim of this study was to measure mucosal butyrate oxidation in UC (involved and noninvolved colon) and in pouchitis and to study the relationship with endoscopic as well as histological disease activity...
  24. ncbi request reprint The value of myenteric plexitis to predict early postoperative Crohn's disease recurrence
    Marc Ferrante
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Gastroenterology 130:1595-606. 2006
    ..Unequivocal histologic markers predicting recurrence have not been identified. We assessed the predictive value of neural lesions for early endoscopic CD recurrence and long-term reintervention risk...
  25. pmc Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease
    Severine Vermeire
    Department of Internal Medicine, Division of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Gut 56:1226-31. 2007
    ..Concomitant use of immunosuppressives (IS) reduces the risk of ATI formation...
  26. ncbi request reprint Transmission of CARD15 (NOD2) variants within families of patients with inflammatory bowel disease
    Nele Esters
    Department of Gastroenterology, UZ Gasthuisberg, Leuven, Belgium
    Am J Gastroenterol 99:299-305. 2004
    ..Since nothing is known about the transmission of these variants within families, this was the subject of our study in Flemish patients with inflammatory bowel disease (IBD) and their healthy relatives...
  27. ncbi request reprint Focus on mechanisms of inflammation in inflammatory bowel disease sites of inhibition: current and future therapies
    Gert Van Assche
    Division of Gastroenterology, University of Leuven Hospitals, Herestraat 49, B 3000 Leuven, Belgium
    Gastroenterol Clin North Am 35:743-56. 2006
    ..The advent of newer anti-TNF agents is only postponing the answer...
  28. ncbi request reprint C-reactive protein as a marker for inflammatory bowel disease
    Severine Vermeire
    Department of Medicine, Division of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 10:661-5. 2004
    ..However, whether we need to include CRP as an inclusion criterion for future trials with biologicals is still a matter of debate...
  29. ncbi request reprint Novel biological strategies in inflammatory bowel diseases
    Severine Vermeire
    Department of Medicine, Division of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 10:S44-51. 2004
  30. ncbi request reprint A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis
    Geert D'Haens
    University Hospital Gasthuisberg, Leuven, Belgium
    Gastroenterology 132:763-86. 2007
  31. doi request reprint Genetic risk profiling and prediction of disease course in Crohn's disease patients
    Liesbet Henckaerts
    Department of Medicine, Gastroenterology Section, Catholic University of Leuven, Leuven, Belgium
    Clin Gastroenterol Hepatol 7:972-980.e2. 2009
    ..We examined the influence of recently discovered CD-associated susceptibility loci on changes in disease behavior and evaluated whether a genetic risk model for disease progression could be generated...
  32. ncbi request reprint Functional expression of 4-1BB (CD137) in the inflammatory tissue in Crohn's disease
    Philippe Maerten
    Clinical Immunology, University Hospital, Katholieke Universiteit Leuven, Leuven, Belgium
    Clin Immunol 112:239-46. 2004
    ..Taken together, our data suggest that 4-1BB/4-1BBL interactions contribute to the persistence of gut inflammation in CD...
  33. doi request reprint Does the biomarker 15N-lactose ureide allow to estimate the site of fermentation of resistant starch?
    Lieselotte Cloetens
    Department of Gastrointestinal Research, Katholieke Universiteit Leuven, Leuven, Belgium
    Eur J Nutr 47:217-23. 2008
    ..Since about 80% of the cumulative urinary (15)N was recovered within 24 h, it was concluded that the biomarker (15)N-LU was useful to monitor processes in the proximal colon rather than in the distal colon...
  34. ncbi request reprint Pancreatic autoantibodies in inflammatory bowel disease
    Sofie Joossens
    Department of Gastroenterology, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium
    Inflamm Bowel Dis 10:771-7. 2004
    ..We studied PABs in patients with inflammatory bowel disease (IBD), unaffected family members, and control subjects...
  35. ncbi request reprint Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease
    Peter Suenaert
    Department of Gastroenterology, University Hospital Gasthuisberg, Catholic University Leuven, Leuven, Belgium
    Am J Gastroenterol 97:2000-4. 2002
    ....
  36. ncbi request reprint Evaluation of short-term responsiveness and cutoff values of inflammatory bowel disease questionnaire in Crohn's disease
    Tibor Hlavaty
    University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 12:199-204. 2006
    ..Whereas the validity and reproducibility of the IBDQ have been extensively studied, there are limited data on its short-term responsiveness and cutoff values for remission and partial clinical response...
  37. ncbi request reprint The influence of inulin on the absorption of nitrogen and the production of metabolites of protein fermentation in the colon
    Karen P Geboes
    Laboratory of Digestion and Absorption, Department of Gastroenterology, University Hospital Gasthuisberg, Catholic University of Leuven, Herestraat 49, 3000 Leuven, Belgium
    Br J Nutr 96:1078-86. 2006
    ..Further studies are warranted to confirm these results in a larger cohort...
  38. ncbi request reprint Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors
    Tibor Hlavaty
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 13:372-9. 2007
    ..Predictors of response could improve selection of patients with a higher probability of favorable outcomes and could improve the safety profile. We aimed to develop a predictive model for the response to infliximab in CD...
  39. ncbi request reprint Influence of resistant starch alone or combined with wheat bran on gastric emptying and protein digestion in healthy volunteers
    Vicky De Peter
    Department of Gastrointestinal Research, University Hospital Gasthuisberg, Leuven, Belgium
    Scand J Gastroenterol 42:1187-93. 2007
    ..The purpose of the study was to investigate the influence of RS type 3 (retrograded amylose) alone or combined with wheat bran on gastric emptying (GE) and protein assimilation...
  40. ncbi request reprint Influence of long-term administration of lactulose and Saccharomyces boulardii on the colonic generation of phenolic compounds in healthy human subjects
    Vicky De Preter
    Department of Gastrointestinal Research, University Hospital Leuven, Herestraat 49, 3000 Leuven, Belgium
    J Am Coll Nutr 25:541-9. 2006
    ..In addition, the influence of a long-term dietary intake on different gastrointestinal parameters was investigated...
  41. pmc Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment
    Ingrid Arijs
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    PLoS ONE 4:e7984. 2009
    ..We investigated the impact of anti-inflammatory therapy with infliximab on the mucosal gene expression of AMPs in IBD...
  42. ncbi request reprint Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease
    Severine Vermeire
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Am J Gastroenterol 97:2357-63. 2002
    ..The aim of this study was to assess whether demographic or clinical parameters influence short-term response to infliximab...
  43. doi request reprint Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab
    Zhe Li
    Laboratory of Experimental Immunology, Catholic University of Leuven, Leuven, Belgium
    Inflamm Bowel Dis 16:1299-310. 2010
    ..Therefore, we investigated the effect of infliximab (IFX) therapy on Forkhead box protein3 (Foxp3) T cells in blood and intestinal mucosa from Crohn's disease (CD) and ulcerative colitis (UC)...
  44. doi request reprint Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease
    Fabian Schnitzler
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 15:1295-301. 2009
    ..Infliximab (IFX) treatment induces mucosal healing (MH) in patients with Crohn's disease (CD) but the impact of MH on the long-term outcome of IFX treatment in CD is still debated...
  45. ncbi request reprint Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
    Filip Baert
    Department of Internal Medicine, Division of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    N Engl J Med 348:601-8. 2003
    ..We evaluated the clinical significance of these antibodies in patients with Crohn's disease...
  46. ncbi request reprint Overexpression of indoleamine 2,3-dioxygenase in human inflammatory bowel disease
    Anna Maria Wolf
    Department of Medicine, Division of Gastroenterology and Hepatology, University Hospital Innsbruck, Internal Medicine, Innsbruck, Austria
    Clin Immunol 113:47-55. 2004
    ..In summary, high local expression of IDO may represent an anti-inflammatory mechanism tempting to counterbalance the tissue-damaging effects of activated T-cells infiltrating the colonic mucosa in IBD...
  47. ncbi request reprint Decreased lamina propria effector cell responsiveness to interleukin-10 in ileal Crohn's disease
    Stefaan Colpaert
    Laboratory of Experimental Immunology, University Hospital and Katholieke Universiteit Leuven, Leuven, Belgium
    Clin Immunol 102:68-76. 2002
    ..We conclude that IL-10 exhibits poor anti- and even potential proinflammatory effects on ileal Crohn's disease lamina propria. These data might explain the lack of therapeutic efficacy when IL-10 is given to Crohn's disease patients...
  48. ncbi request reprint Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis
    Joris Arts
    Department of Internal Medicine, University Hospital, Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Inflamm Bowel Dis 10:73-8. 2004
    ..It remains unclear if this treatment affects the course of the disease in the long run. We investigated the long-term efficacy and safety in 86 patients with ulcerative colitis treated with i.v. CSA at our center...
  49. doi request reprint Anti-alpha-enolase antibodies in patients with inflammatory Bowel disease
    Nathalie Vermeulen
    Department of Internal Medicine, University Hospital Leuven, Leuven, Belgium
    Clin Chem 54:534-41. 2008
    ..alpha-Enolase has been proposed as a target antigen in IBD. We evaluated the prevalence and diagnostic value of anti-alpha-enolase antibodies in IBD and related disorders...
  50. doi request reprint Management of acute severe ulcerative colitis
    Gert Van Assche
    Division of Gastroenterology, Leuven University Hospitals, Leuven, Belgium
    Gut 60:130-3. 2011
    ..Whereas prolonged exposure to steroids predisposes to an increased rate of peri-operative complications it is still debated whether cyclosporine or infliximab increase peri-operative morbidity in ulcerative colitis...
  51. ncbi request reprint Predictors of early response to infliximab in patients with ulcerative colitis
    Marc Ferrante
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 13:123-8. 2007
    ..Our objective is to report the outcome of infliximab (IFX) in ulcerative colitis (UC) patients from a single center and to identify predictors of early clinical response...
  52. ncbi request reprint Endoscopic therapy of strictures in Crohn's disease
    Gert Van Assche
    Division of Gastroenterology, Leuven University Hospital, Leuven, Belgium
    Inflamm Bowel Dis 13:356-8; discussion 362-3. 2007
  53. doi request reprint Familial aggregation and antimicrobial response dose-dependently affect the risk for Crohn's disease
    Marie Joossens
    Division of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 16:58-67. 2010
    ..Our aim was to test whether a combination of CD-associated genes involved in innate immunity and/or antibody responses to microbial antigens may be valuable in identifying healthy relatives at risk...
  54. doi request reprint Cystic fibrosis transmembrane conductance regulator gene polymorphisms in patients with primary sclerosing cholangitis
    Liesbet Henckaerts
    Department of Gastroenterology, University Hospital Gasthuisberg, Catholic University of Leuven, Herestraat 49, B 3000 Leuven, Belgium
    J Hepatol 50:150-7. 2009
    ..The histological features in the liver of PSC patients are similar to those observed in cystic fibrosis (CF). Our aim was to study whether variants in the CFTR gene are associated with the occurrence and/or evolution of PSC...
  55. doi request reprint Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial
    Geert R D'Haens
    Department of Gastroenterology, Leuven University Hospitals, Leuven, Belgium
    Gastroenterology 135:1123-9. 2008
    ..Goal: We sought to examine whether metronidazole for 3 months together with azathioprine (AZA) for 12 months is superior to metronidazole alone to reduce recurrence of postoperative CD in "high-risk" patients...
  56. doi request reprint (Auto)antibodies in inflammatory bowel diseases
    Severine Vermeire
    Department of Gastroenterology, University Hospitals Leuven Belgium, UZ Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Gastroenterol Clin North Am 37:429-38, vii. 2008
    ..However, currently, they have no place in the diagnostic work up. Their real promise may lie in their use as surrogate markers of complicated aggressive disease as shown in various retrospective studies, but prospective data are lacking...
  57. pmc New serological markers in inflammatory bowel disease are associated with complicated disease behaviour
    Marc Ferrante
    Department of Gastroenterology, University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Gut 56:1394-403. 2007
    ....
  58. ncbi request reprint The value of serologic markers in indeterminate colitis: a prospective follow-up study
    Sofie Joossens
    Gastroenterology Unit, Department of Pathology, U Z Gasthuisberg, Leuven, Belgium
    Gastroenterology 122:1242-7. 2002
    ..We evaluated the value of anti-Saccharomyces cerevisiae antibodies (ASCA) and perinuclear antineutrophil cytoplasmic antibodies (pANCA) to increase diagnostic accuracy in categorizing IC...
  59. ncbi request reprint Medical treatment of inflammatory bowel diseases
    Gert Van Assche
    Division of Gastroenterology, University of Leuven, Leuven, Belgium
    Curr Opin Gastroenterol 21:443-7. 2005
    ..Despite the advent of the anti-TNF agent, infliximab, an important unmet medical need characterizes the medical treatment of inflammatory bowel diseases. This review aims to summarize recent progress in the field...
  60. ncbi request reprint Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease
    Gert Van Assche
    Division of Gastroenterology, Univ Hospital Leuven, 49 Herestraat, B 3000 Leuven, Belgium
    Am J Physiol Gastrointest Liver Physiol 288:G169-74. 2005
    ....
  61. ncbi request reprint Validation of lactose[15N,15N]ureide as a tool to study colonic nitrogen metabolism
    Karen P Geboes
    Laboratory of Digestion and Absorption, Deptartment of Gastroenterology, University Hospital Gasthuisberg, Catholic University of Leuven, Herestraat 49, 3000 Leuven, Belgium
    Am J Physiol Gastrointest Liver Physiol 288:G994-9. 2005
    ..This instillation study shows that lactose[15N,15N]ureide is a tool with good properties to investigate the effect of different types of carbohydrates on nitrogen metabolism in the proximal colon in vivo...
  62. ncbi request reprint Medical management of postoperative recurrence in Crohn's disease
    Gert Van Assche
    Division of Gastroenterology, Department of Internal Medicine, University Hospital Leuven, 49 Herestraat, B 3000 Leuven, Belgium
    Gastroenterol Clin North Am 33:347-60, x. 2004
    ..Future well designed collaborative trials with specified end points are needed to optimize clinical practice in the prevention of postoperative Crohn's disease recurrence...
  63. ncbi request reprint Validation of a new test meal for a protein digestion breath test in humans
    Karen P Geboes
    Department of Gastroenterology, University Hospital Gasthuisberg, Catholic University of Leuven, 3000 Leuven, Belgium
    J Nutr 134:806-10. 2004
    ..The incorporation of differently labeled substrates into a single test meal allows the assessment of different gastrointestinal processes in the overall assimilation of proteins...
  64. ncbi request reprint Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis
    Gert Van Assche
    Department of Gastroenterology, University of Leuven, 49, Herestraat, Leuven 3000, Belgium
    Gastroenterology 125:1025-31. 2003
    ..Our single center, randomized, double-blind, controlled trial aimed to evaluate the additional clinical benefit of 4 mg/kg over 2 mg/kg IV cyclosporine in the acute treatment of severe UC...
  65. ncbi request reprint Toll-like receptor-1, -2, and -6 polymorphisms influence disease extension in inflammatory bowel diseases
    Marie Pierik
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 12:1-8. 2006
    ..This is underscored by the finding of the association between CARD15 variants and Crohn's disease (CD) and D299G in Toll-like receptor (TLR) 4 and IBD. Our aims were to study nonsynonymous polymorphisms in other TLR genes in IBD...
  66. ncbi request reprint Antiadhesion molecule therapy in inflammatory bowel disease
    Gert Van Assche
    Division of Gastroenterology, University Hospital Leuven, Belgium
    Inflamm Bowel Dis 8:291-300. 2002
    ..In the near future, these novel biological agents may prove valuable therapeutic tools in the management of refractory IBD...
  67. ncbi request reprint In vitro analysis of interferon gamma (IFN-gamma) and interleukin-12 (IL-12) production and their effects in ileal Crohn's disease
    Stefaan Colpaert
    Laboratory of Experimental Immunology, University Hospital Gasthuisberg and Catholic University of Leuven, Belgium
    Eur Cytokine Netw 13:431-7. 2002
    ..Therapies aiming at neutralisation of IFN-gamma or IL-12 are therefore unlikely to replace anti-TNF, but they might provide an additive or synergistic effect...
  68. ncbi request reprint Safety issues with biological therapies for inflammatory bowel disease
    Gert Van Assche
    Division of Gastroenterology, University of Leuven Hospitals, Leuven, Belgium
    Curr Opin Gastroenterol 22:370-6. 2006
    ..The purpose of this review is to summarize recent evidence describing specific complications associated with the use of biological therapy derived from controlled trials and from post-marketing surveillance...
  69. ncbi request reprint Emerging biological treatments in inflammatory bowel diseases
    Gert Van Assche
    Division of Gastroenterology, University of Leuven, Leuven, Belgium
    Dig Dis 24:131-6. 2006
    ..As illustrated by unexpected but devastating brain infections with anti-adhesion molecules, clinicians should be aware that the powerful immunomodulatory capacity of biologicals necessitates a rigorous safety follow-up...
  70. doi request reprint Immunosuppression in inflammatory bowel disease: traditional, biological or both?
    Gert Van Assche
    Division of Gastroenterology, University of Leuven Hospitals, Leuven, Belgium
    Curr Opin Gastroenterol 25:323-8. 2009
    ..To focus on the emerging clinical evidence for the use of traditional immunosuppressives and biologicals in the treatment of inflammatory bowel disease...
  71. doi request reprint Serum sickness, encephalitis and other complications of anti-cytokine therapy
    Severine Vermeire
    University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium
    Best Pract Res Clin Gastroenterol 23:101-12. 2009
    ..We discuss the safety aspects of the biological agents in this chapter and, where available, give ways to prevent and/or treat them...
  72. doi request reprint Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity
    Severine Vermeire
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Clin Gastroenterol Hepatol 8:357-63. 2010
    ..We investigated whether a simpler tool, the Harvey-Bradshaw Index, was equally effective in assessing disease severity...
  73. doi request reprint The potential for disease modification in Crohn's disease
    G Van Assche
    Department of Gastroenterology, University Hospital Leuven, 3000 Leuven, Belgium
    Nat Rev Gastroenterol Hepatol 7:79-85. 2010
    ....
  74. pmc Role of genetics in prediction of disease course and response to therapy
    Severine Vermeire
    Department of Gastroenterology, University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    World J Gastroenterol 16:2609-15. 2010
    ..Nevertheless, the importance and necessity of pharmacogenetic studies will increase further as more therapeutic classes are being developed...
  75. ncbi request reprint A critical assessment of new therapies in inflammatory bowel disease
    Paul Rutgeerts
    Department of Medicine, Division of Gastroenterology, University of Leuven, Belgium
    J Gastroenterol Hepatol 17:S176-85. 2002
    ..Probiotics are an attractive treatment option for IBD but studies so far are small and data are not yet convincing...
  76. ncbi request reprint Medical therapy for Crohn's disease strictures
    Gert Van Assche
    Division of Gastroenterology, Leuven University Hospital, Herestraat 49, 3000 Leuven, Belgium
    Inflamm Bowel Dis 10:55-60. 2004
    ..Specific medical therapy aimed at preventing or reversing intestinal fibrosis is not yet available, but candidate molecules are emerging from research in the liver and in other organs...
  77. ncbi request reprint Crohn's disease and month of birth
    Marc Van Ranst
    Laboratory of Clinical and Epidemiological Virology, Department of Microbiology and Immunology, Rega Institute for Medical Research, University of Leuven, Leuven, Belgium
    Inflamm Bowel Dis 11:597-9. 2005
    ..Some studies suggested an association between the month of birth and the later development of IBD. We studied this putative relationship in a large cohort of Belgian patients with Crohn's disease (CD)...
  78. ncbi request reprint Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease
    Karel Geboes
    Universitair Ziekenhuis St Rafael, Afdeling Pathologie, Leuven, Belgium
    Curr Med Res Opin 21:1741-54. 2005
    ....
  79. ncbi request reprint Association of organic cation transporter risk haplotype with perianal penetrating Crohn's disease but not with susceptibility to IBD
    Severine Vermeire
    Department of Gastroenterology, UZ Gasthuisberg, Leuven, Belgium
    Gastroenterology 129:1845-53. 2005
    ..We studied mutation prevalence, assessed phenotypic expression, and performed conditional analysis to examine evidence for gene-gene interactions...
  80. ncbi request reprint Dry preparation for virtual CT colonography with fecal tagging using water-soluble contrast medium: initial results
    Didier Bielen
    Department of Radiology, University Hospital Gasthuisberg, K U Leuven, Herestraat 49, 3000 Leuven, Belgium
    Eur Radiol 13:453-8. 2003
    ..Dry bowel preparation and VCTC is a promising approach towards a patient-friendly colon cancer-screening setup...
  81. ncbi request reprint Pharmacogenetics in inflammatory bowel disease
    Marie Pierik
    Department of Gastro enterology, University of Hospital Gasthuisberg, Leuven, Belgium
    World J Gastroenterol 12:3657-67. 2006
    ..An effort should be made to collect genomic DNA from all patients enrolled in clinical drug trials after appropriate informed consent for pharmacogenetic studies...
  82. ncbi request reprint The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases
    Severine Vermeire
    Department of Medicine, Division of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Nat Clin Pract Gastroenterol Hepatol 2:580-6. 2005
    ..Until there are more data, the use of CRP and of other biomarkers should be seen as an additional tool that aids clinical observation and physical examination, but that cannot replace it...
  83. doi request reprint Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials
    Brian G Feagan
    Robarts Clinical Trials, Robarts Research Institute, University of Western Ontario, 100 Perth Dr, London, ON, Canada N6A 5K8
    JAMA 299:1690-7. 2008
    ..Maintenance therapy for Crohn disease features the use of immunosuppressive drugs, which are associated with an increased risk of infection. Identification of safe and effective maintenance strategies is a priority...
  84. ncbi request reprint Natalizumab for active Crohn's disease
    Subrata Ghosh
    Western General Hospital, Edinburgh, United Kingdom
    N Engl J Med 348:24-32. 2003
    ..In chronic inflammatory conditions such as Crohn's disease, the migration of leukocytes from the circulation into the parenchyma and their activation within inflammatory sites are mediated in part by alpha4 integrins...
  85. ncbi request reprint Natalizumab induction and maintenance therapy for Crohn's disease
    William J Sandborn
    Mayo Clinic, Rochester, Minn 55905, USA
    N Engl J Med 353:1912-25. 2005
    ..Natalizumab, a humanized monoclonal antibody against alpha4 integrin, inhibits leukocyte adhesion and migration into inflamed tissue...
  86. ncbi request reprint Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
    Stephen B Hanauer
    Department of Gastroenterology and Nutrition, University of Chicago Medical Center, Chicago, IL 60637, USA
    Lancet 359:1541-9. 2002
    ..We did a randomised controlled trial to assess the benefit of maintenance infliximab therapy in patients with active Crohn's disease who respond to a single infusion of infliximab...
  87. ncbi request reprint NOD2/CARD15 mutations in Croatian patients with Crohn's disease: prevalence and genotype-phenotype relationship
    Silvija Cukovic-Cavka
    Division of Gastroenterology dDepartment of Pathology, University Hospital Rebro, Zagreb, Croatia
    Eur J Gastroenterol Hepatol 18:895-9. 2006
    ....
  88. ncbi request reprint Anti-inflammatory activity of a pteridine derivative (4AZA2096) alleviates TNBS-induced colitis in mice
    Chong Shen
    Laboratory of Experimental Immunology, Faculty of Medicine, Katholieke Universiteit Leuven, Belgium
    J Interferon Cytokine Res 26:575-82. 2006
    ....
  89. ncbi request reprint Long-term effectiveness of azathioprine in IBD beyond 4 years: a European multicenter study in 1176 patients
    Martin H Holtmann
    First Department of Medicine, Johannes Gutenberg University, Mainz, Germany
    Dig Dis Sci 51:1516-24. 2006
    ..In all other CD patients and for UC patients in general, continuation seems beneficial. These results support a novel differential algorithm for long-term azathioprine therapy in IBD...
  90. ncbi request reprint Lymphotoxin alpha gene in Crohn's disease patients: absence of implication in the response to infliximab in a large cohort study
    Vinciane Dideberg
    Department of Human Genetics, CHU Sart Tilman, University of Liege, 4000 Liege, Belgium
    Pharmacogenet Genomics 16:369-73. 2006
    ..We could not confirm an association between the LTA locus and clinical or biological response to infliximab in a large cohort of CD patients...
  91. ncbi request reprint The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients
    Brian G Feagan
    Robarts Research Institute, University of Western Ontario, London, Canada
    Am J Gastroenterol 102:794-802. 2007
    ..The impact of infliximab induction and maintenance therapy on health-related quality of life (HRQL) was evaluated in patients with ulcerative colitis (UC)...
  92. ncbi request reprint Significance of anti-sacharomices cerevisiae antibodies (ASCA) in patients with inflammatory bowel diseases in Romania
    Carmen Monica Preda
    Center of Gastroenterology and Hepatology, Fundeni Clinical Institute, Str Fundeni no 258, 72437 Bucharest, Romania
    Rom J Gastroenterol 14:23-6. 2005
    ..Anti-Sacharomyces cerevisiae antibodies (ASCA) represent the immunologic marker correlated with Crohn's disease because of their high specificity (80-95%). The aim of this study is to confirm their value in a Romanian population with IBD...
  93. ncbi request reprint Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial
    Stephen B Hanauer
    Department of Medicine, University of Chicago Medical Center, Chicago, Illinois, USA
    Gastroenterology 127:723-9. 2004
    ..The aim of the current trial was to compare 6-mercaptopurine (6-MP) and mesalamine with placebo for the prevention of clinical, endoscopic, and radiographic recurrence of Crohn's disease after resection and ileocolic anastomosis...
  94. ncbi request reprint Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease
    Stephen B Hanauer
    Department of Gastroenterology and Nutrition, University of Chicago Medical Center, IL 60637, USA
    Clin Gastroenterol Hepatol 2:542-53. 2004
    ..The effect of different treatment regimens on antibody responses to infliximab and their clinical significance was examined by using data from ACCENT I...
  95. ncbi request reprint Certolizumab pegol for the treatment of Crohn's disease
    William J Sandborn
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    N Engl J Med 357:228-38. 2007
    ..Certolizumab pegol is a pegylated humanized Fab' fragment that binds tumor necrosis factor alpha...
  96. ncbi request reprint Hyperresponsiveness of the mucosal barrier in Crohn's disease is not tumor necrosis factor-dependent
    Peter Suenaert
    Division of Gastroenterology, Montreal General Hospital, McGill University Health Centre, McGill University, Montreal, Quebec, Canada
    Inflamm Bowel Dis 11:667-73. 2005
    ....
  97. ncbi request reprint Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis
    Walter Reinisch
    Univ Klinik Innere Medizin IV, AKH Wien, Vienna, Austria, and Division of Gastroenterology, Hospital Leuven, Belgium
    Inflamm Bowel Dis 13:1135-40. 2007
    ..Impairment of health-related quality of life, employment, and productivity has been documented in patients with moderate to severe ulcerative colitis...
  98. ncbi request reprint Infliximab maintenance therapy for fistulizing Crohn's disease
    Bruce E Sands
    Gastrointestinal Unit, Massachusetts General Hospital, and Harvard Medical School, Boston 02114, USA
    N Engl J Med 350:876-85. 2004
    ..It is not known whether infliximab is an effective maintenance therapy for patients with fistulas...
  99. pmc Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4
    Cecile Libioulle
    Unit of Animal Genomics, GIGA R and Faculty of Veterinary Medicine, University of Liege, Liege, Belgium
    PLoS Genet 3:e58. 2007
    ..Our results identify a major new susceptibility locus for CD, and suggest that genetic variants associated with disease risk at this locus could modulate cis-acting regulatory elements of PTGER4...
  100. doi request reprint Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial
    Geert D'Haens
    Imelda Gastrointestinal Clinical Research Centre, Bonheiden, Belgium
    Lancet 371:660-7. 2008
    ..We aimed to compare the effectiveness of early use of combined immunosuppression with conventional management in patients with active Crohn's disease who had not previously received glucocorticoids, antimetabolites, or infliximab...